Studies indicate that ingested oral cyanocobalamin tablets are ineffective New in the treatment of allergic disease, perhaps because Arthritis once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in Treatments its native form that it is believed to exert its therapeutic New effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma Arthritis and allergic rhinitis subjects were treated with B12. Treatments Total IgE, specific IgE and pulmonary New lung functions Arthritis were taken at days 45, 150 and 180 from Treatments baseline. New Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies Arthritis at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day Treatments 0 to Day New 30.3

In January 1997, 62 subjects Arthritis who had been the placebos in the 1995 study were invited to receive Treatments the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 New treatment, and 5 not. 12 of the 15 reported Arthritis at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the Treatments and New spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily subjects maintained Arthritis a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded on average a greater reduction in symptoms Treatments and in antihistamine use than the New placebo group (n=9). The Arthritis results yielded reductions (0.1>p>0.01) in total weekly Treatments symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. The results New tend to replicate those of the Arthritis studies on injectable cyanocobalamin.1 Treatments.